I don't normally post but this has been a very disappointing result from BOT. I am grateful for all I've read these past days and am holding as I believe in the products and potential of our company. I would like to know who is responsible for quality control within a clinical trial and if anyone going to the AGM please ask this. A clinical trial is an expensive and critical exercise and surely within Botanix someone must have been responsible for this task?
Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-546
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
0.015(4.76%) |
Mkt cap ! $597.3M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.3¢ | $1.265M | 3.862M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 129446 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 131308 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |